Affiliation:
1. First Moscow State Medical University named after I.M. Sechenov
Abstract
The article tells about major anticoagulant medications used in cancer patients taking into account the pathogenesis of hypercoagulation status in these patients: oral anticoagulants, heparin medications, selective factor Xa-inhibitors. The main advantages of low molecular weight heparins versus unfractionated heparin are described. Recommendations for the prevention of thrombotic complications in cancer patients are provided. Possible complications of heparin therapy are reviewed, and the prevention methods are suggested.
Reference31 articles.
1. Gray E, MuLLoy B, Barrowcliffe TW. Heparin and low-molecularweight heparin. Thromb Haemost, 2008, 99: 807-18.
2. Makatsariya A.D., Vorob'ev A.V., Bitsadze V.O. Zlokachestvennye novoobrazovaniya, trombofiliya, trombozy. Monografiya. Triada-Kh, M., RF, 2008, 650 str.
3. Donati MB, Falanga A. Patogenetic Mechanisms of Thrombosis in Malignancy. Acta Haematol, 2001, 106: 18-24.
4. van Dongen CJ, Mac Gillavry MR, Prins MH. Once versus twice daily LMWH for the initial treatment of venous thromboembolism. Cochrane Database Syst. Rev, 2005, Issue 3. Art. № CD003074.
5. Falanga A, Marchetti M, Vignoli A. Pathogenesis of thrombosis in cancer. Thromb and cancer, 2004, 30: 11-23.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献